What is Amnio Technology?
Amnio Technology operates at the intersection of biotechnology and clinical wound care, specializing in the development and manufacturing of high-quality, chorion-free amniotic allografts. Their flagship PalinGen product line is engineered to address critical gaps in orthopedic and wound management, specifically targeting the reduction of graft-versus-host autoimmune responses. By maintaining rigorous regulatory standards and focusing on clinical efficacy, the company has established itself as a trusted partner for healthcare providers nationwide, effectively bridging the gap between advanced biological research and practical, patient-centric medical applications.
How much funding has Amnio Technology raised?
Amnio Technology has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Amnio Technology
PPP
Public-Private Partnership
What's next for Amnio Technology?
With the successful acquisition of this late-stage financing, Amnio Technology is poised to scale its manufacturing infrastructure and broaden its commercial reach. The strategic focus will likely shift toward deepening market penetration for the PalinGen brand while potentially exploring new indications for their regenerative therapies. As the company navigates the complexities of the biotech landscape, this capital provides the necessary runway to sustain long-term growth, enhance product development pipelines, and solidify its status as a leader in the rapidly evolving field of regenerative medicine.
See full Amnio Technology company page
